EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

C Formichi, W Baronti, G de Gennaro, M Cerrai Ceroni, L Nigi, L Rizzo, F Dotta

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02369-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von C Formichi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy. caterina.formichi@…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Università degli Studi di Siena.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.

Methods

We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.

Results

Oral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events.

Conclusion

In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsHumansFemaleMaleAdministration, OralInjections, SubcutaneousRetrospective StudiesMiddle AgedAgedFollow-Up StudiesBlood GlucoseGlycated HemoglobinSemaglutide

Stichwörter der Autor:innen

GLP1-RASemaglutideTailored treatmentType 2 diabetes

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucoseGlycated HemoglobinSemaglutide

Autor:innen und Institutionen

  • Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy. caterina.formichi@unisi.it.
  • Fondazione Umberto Di Mario, Toscana Life Science, 53100, Siena, Italy. caterina.formichi@unisi.it.
  • Metabolic Diseases and Diabetes Unit, Misericordia Hospital, USL Toscana sud est, 58100, Grosseto, Italy.
  • Fondazione Umberto Di Mario, Toscana Life Science, 53100, Siena, Italy.
  • Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Università degli Studi di Siena

Zitieren

APA

Formichi, C., Baronti, W., de Gennaro, G., Cerrai Ceroni, M., Nigi, L., Rizzo, L., & Dotta, F. (2024). Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02369-4

Vancouver

Formichi C, Baronti W, de Gennaro G, Cerrai Ceroni M, Nigi L, Rizzo L, et al. Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02369-4

BibTeX
@article{Formichi2024,
  author = {Formichi, C and Baronti, W and de Gennaro, G and Cerrai Ceroni, M and Nigi, L and Rizzo, L and Dotta, F},
  title = {Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02369-4}
}
Kostenlos starten →